In a recent issue, Duca and colleagues reported the results of a first-in-human phase I study of PCA062, an antibody–drug conjugate (ADC) targeting P-cadherin (CDH3), in patients with CDH3-positive solid tumors (1). The clinical development of PCA062 was, however, terminated due to its limited antitumor activity at MTD. Here, we would like to point out that the therapeutic development of a third-generation CDH3-ADC should still be considered as an interesting strategy for pancreatic adenocarcinoma (PAAD).

PAAD is one of the most pejorative cancers with few treatment options. The most represented tumors in the Duca and colleagues’ study were esophagus and head and neck squamous cell carcinomas (respectively, ESCC n = 9, and HNSCC n = 6); the detailed information on the tumor type was not available for the other 31 patients enrolled, impeding to identify the number of patients with PAAD (at least one). Although inferior to expression...

You do not currently have access to this content.